All News

Conv3.jpg

EULAR 2024 - Day 1 Report

Jack Cush, MD

Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

Read Article
hand stopping falling dominos

Can we prevent psoriatic arthritis?

Antoni Chan, MD, PhD

Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how early interventions in PsO may augment the progression to PsA. At #EULAR2024, there are a few presentations on this topic that will help us understand this progression from PsO to PsA better.

Read Article
RA,polyarticular,black,rheumatoid

EULAR 2024: New drugs for RA?

Aurelie Najm, MD, PhD

Several abstracts are presenting new compounds, targeting either RA well-known inflammatory pathways or offering new mechanisms of action or therapeutic sequences; these are summarized below.

Read Article
lupus SLE

SLE Preview: abolishing refractory with CAR-T and better B-cell therapies

Md Yuzaiful Md Yusof, MRCP(UK), PhD

Inhibition of B cell activating factor (BAFF) and B cell depletion are the two most evaluated strategies over the last 15 years in the field of SLE therapeutics, with licensing of belimumab and off-label use of rituximab.

Read Article
biosim.sign_.jpg

Humira Clobbers Biosimilars in Battle for Part D Coverage

Medpage Today

Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar versions currently approved, researchers found.

Read Article
medical.marijuana

Cannabis Use is Common, But is it Safe?

Jack Cush, MD

Two current JAMA reports suggest that cannabis use is not only common, but that if heavily used may increase mortality rates.

Read Article
#EULAR2024 OP0043 Data from UK BILAG-BR registry showed in n>100 patients w neuropsychiatric #lupus (NPSLE), over 2/3 improved with rituximab. NPSLE tended to occur with other #SLE features and with high level of organ damage @RheumNow https://t.co/q5olZgr6Pt

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
OP0137 is comparative analysis of clinical efficacy & drug retention of b/tsDMARDs >1/2 D2T RA pts starting JAKi, RTX, IL-6Ri, or TNFi, but ~1/3 w abatacept, achieved remission or low disease activity in 6m & maintained consistent drug retention for 2yrs @RheumNow #EULAR2024

Mrinalini Dey DrMiniDey ( View Tweet)

OP0131 on occurrence & predictors of #DMARD treatment failure in #RA 8% of pts failed ≥3 b/tsDMARDs with ~4yrs to failure In pts starting first b/tsDMARD, up to 25% fail ≥2 b/tsDMARDs in 3yrs Risk of fulfilling EULAR D2T criterion 1 ➡️ 2.3% in first 5yrs @RheumNow #EULAR2024

Mrinalini Dey DrMiniDey ( View Tweet)

#EULAR2024 OP0076 UK multicentre cohort study showed rituximab was effective in systemic features of #Sjogren in children & adults. One in 6 lost response in subsequent cycle due to antidrug antibodies. Humanised or type 2 antiCD20Ab in the future could improve this @RheumNow https://t.co/duYpr2yKGB

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Novel B cell depleters! Bispecific T cell engagers (BiTEs) being studied for #SLE & #RA as a way to get CAR-T cell like responses but more accessible w/less risk for CK release syndrome. #EULAR24 T cell-engaging therapies — BiTEs and beyond | Nature Reviews Clinical Oncology

TheDaoIndex KDAO2011 ( View Tweet)

OP0053 #EULAR2024 @RheumNow #EULARBest Effect of #RTX in preclinical #RheumatoidArthritis RA-risk pts given 1 dose PBO or 1000mg RTX RTX in RA-risk pts delayed onset of RA by 1yr; no benefit on QoL Pts developing RA: RTX didn't alter PROs or disease severity when developing RA

Mrinalini Dey DrMiniDey ( View Tweet)

AMPLIFIED study: abatacept vs adalimumab in RF+ACPA+ early RA Not a single blink of difference. Maybe for high CCP titre but the inverse for low CCP. Sadly, theoretical mechanistic benefit doesn’t always wash out. We’ll keep on looking for predictors #EULAR2024 OP0007 @RheumNow https://t.co/IswCub9lLn

Links:

David Liew drdavidliew ( View Tweet)
CAR-T effective B cell depletion preserving plasma cell function @rheumnow #EULAR2024 https://t.co/mYmwC2cV6e

Links:

Peter Nash drpnash ( View Tweet)
« CAR T cells can change the therapeutic scenario: a short treatment for a prolonged efficacy » says G. Schett Are we finally looking at the « visionary scenario »? @RheumNow #EULAR2024 https://t.co/tzfDormeIl

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Pt with LN, endocarditis, pericarditis, arthritis, rash failed CTX, MMF, BEL, and SOC. She is 1000 days post CAR-T cell. Off immunomodulating drugs. #SLE in remission clinically and serologically. - Dr G Schett #EULAR24 @RheumNow https://t.co/3vdMtO6VWI

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX) 870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

Grappa difficult to treat PsA meeting - SLR, Patient & rheumo survey, definition eg - fail 1 csDMARD & 2 bDMARDs different MOA - names matter suggest ditch « difficult » for « refractory » @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

Medicare & Optum claims data study of 2851 #RA pts w/ breast cancer (BC). In 3 mos before BC 27028% received bDMARDs. W/in 1st 3 yrs post-BC Dx 24-26% were receiving bDMARDs. 70% of RA pts on steroids without change w/ time https://t.co/51NcXv0xyc https://t.co/461NZiFvDO

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×